전체 프로그램

ADC 890 · Antibody 4097 · CGT 2985 · 다음 갱신 D-6 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved142 programs
AntibodyCurated CoreFDAJohnson & JohnsonApproved

teclistamab (Tecvayli, JNJ-64007957, teclistamab-cqyv)

Relapsed or refractory multiple myeloma · BCMA × CD3

#BCMACD3#Antibody#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 132Status Approved
AntibodyCurated CoreFDARocheApproved

glofitamab (Columvi, RO7082859, glofitamab-gxbm)

Relapsed or refractory diffuse large B-cell lymphoma · CD20 × CD3

#CD20CD3#Antibody#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 90Status Approved
AntibodyCurated CoreFDAGenmabApproved

epcoritamab (Epkinly, GEN3013, Tepkinly, epcoritamab-bysp)

Relapsed or refractory diffuse large B-cell lymphoma and follicular lymphoma · CD20 × CD3

#CD20CD3#Antibody#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 57Status Approved
CGTCurated CoreFDAJohnson & JohnsonApproved

ciltacabtagene autoleucel (Carvykti, cilta-cel, LCAR-B38M, JNJ-68284528)

Relapsed or refractory multiple myeloma · BCMA

#BCMA#CGT#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 29Status Approved
AntibodyCurated CoreFDARegeneronApproved

linvoseltamab (Lynozyfic, REGN5458, linvoseltamab-gcpt)

Relapsed or refractory multiple myeloma after ≥4 prior lines including a PI, an IMiD, and an anti-CD38 antibody · BCMA × CD3

#BCMACD3#Antibody#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 24Status Approved
ADCLimited DatastaleSeagenvedotin combined with the i…Preclinical

recombinant (Brentuximab vedotin, Brentuximab vedotin (recombinant))

Relapsed or Refractory CD30+ Hodgkin's Lymphoma or Anaplastic Large Cell Lymphoma · CD30

#CD30#ADC#Preclinical#Popular#antibody-drug-conjugate+4
Trials 219Status Active
CGTStandard DatabasestaleAstraZenecaPhase 2

autologous CD19-directed chimeric antigen receptor (CAR, autologous CD19-directed chimeric antigen receptor, autologous CD19-directed chimeric antigen receptor (CAR) T-cells)

Relapsed Non Hodgkin Lymphoma; Relapsed Adult ALL · CD19

#CD19#CGT#Phase2#Popular#cell-gene-therapy+5
Trials 154Status Recruiting
AntibodyLimited DatastaleRochePhase 3

Mabthera (Mabthera)

Relapsed Diffuse Large B-cell Lymphoma; Refractory Diffuse Large B-Cell Lymphoma · FRα

#FR#Antibody#Phase3#Popular#monoclonal-antibody+4
Trials 129Status Active
CGTLimited DatastaleNational Taiwan University Hosp…Phase 1

CD19 Chimeric Antigen Receptor (CAR, CD19 Chimeric Antigen Receptor, CD19 Chimeric Antigen Receptor (CAR) T Cells)

Relapsed/Refractory B-Cell Malignancies · CD19

#CD19#CGT#Phase1#Popular#cell-gene-therapy+5
Trials 56Status Active
CGTLimited DatastaleHebei Senlang Biotechnology Inc…Preclinical

CD19+CD22 CAR-T (CD19+CD22 CAR-T)

Relapsed or Refractory B-cell Non-Hodgkin Lymphoma · CD19

#CD19#CGT#Preclinical#Popular#cell-gene-therapy+5
Trials 53Status Active
CGTLimited DatastaleAlaunos TherapeuticsPreclinical

autologous activated T lymphocyte (autologous activated T lymphocyte)

Relapsed or Advanced Gastric Adenocarcinoma; Gastro-esophageal Junction Cancer · Relapsed or Advanced Gastric Adenocarcin

#RelapsedorAdvancedGastricAdenoca#CGT#Preclinical#Popular#cell-gene-therapy+5
Trials 51Status Active
AntibodyCurated CorestaleEpizyme, Inc.Phase 3

Mosunetuzumab (Mosunetuzumab)

Relapsed Hematologic Malignancy; Refractory Hematologic Malignancy · FRα

#FR#Antibody#Phase3#BioJungboMoa-pick#monoclonal-antibody+4
Trials 49Status Recruiting
AntibodyLimited DatastaleEpizyme, Inc.Phase 2

Tafasitamab (Tafasitamab)

Relapsed Hematologic Malignancy; Refractory Hematologic Malignancy · Diffuse Large B-Cell Lymphoma

#DiffuseLargeB-CellLymphoma#Antibody#Phase2#monoclonal-antibody#RelapsedHematologicMalignancy+3
Trials 48Status Discontinued
CGTStandard DatabasestaleOHSU Knight Cancer InstitutePhase 2

Hyper-CVAD (Hyper-CVAD)

Relapsed/Refractory; B-cell Acute Lymphocytic Leukemia · FRα

#FR#CGT#Phase2#cell-gene-therapy#CAR-T+5
Trials 40Status Recruiting
CGTLimited DatastaleSung-Soo ParkPreclinical

IMiD treatment (IMiD treatment)

Multiple Myeloma, Relapsed; Multiple Myeloma (MM) · FRα

#FR#CGT#Preclinical#cell-gene-therapy#CAR-T+5
Trials 39Status Recruiting
CGTStandard DatabasestaleNovartis PharmaceuticalsPhase 2

CTL019 T-cells (CTL019 T-cells)

B-cell Acute Lymphoblastic Leukemia; Relapsed B-cell Acute Lymphoblastic Leukemia · FRα

#FR#CGT#Phase2#cell-gene-therapy#CAR-T+5
Trials 37Status Active
CGTLimited DatastalePersonGen BioTherapeutics (Suzh…Phase 1

CAR T-Cell Infusion (CAR T-Cell Infusion)

Relapsed Acute Lymphoblastic Leukemia (ALL) · Leukemia

#Leukemia#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 33Status Recruiting
CGTLimited DatastaleThe First Affiliated Hospital o…Phase 1

Autologous BCMA CAR-T cells and CD19 CAR-T cells (Autologous BCMA CAR-T cells and CD19 CAR-T cells)

Relapsed or Refractory Multiple Myeloma · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 30Status Active
AntibodyLimited DatastaleMarcela V. Maus, M.D.,Ph.D.Phase 2

Emapalumab (Emapalumab)

Large B-cell Lymphoma; Relapsed Non-Hodgkin Lymphoma · FRα

#FR#Antibody#Phase2#monoclonal-antibody#LargeB-cellLymphoma+2
Trials 29Status Recruiting
ADCStandard DatabasestaleSeagenPhase 2

brentuximab vedotin (Adcetris, Brentuximab Vedotin - induction)

Refractory Peripheral T-Cell Lymphoma; Relapsed Peripheral T-Cell Lymphoma · FRα

#FR#ADC#Phase2#antibody-drug-conjugate#RefractoryPeripheralT-CellLympho+2
Trials 24Status Active

1 / 8 pages

← PreviousNext →